Comments to FDA: Remote Regulatory Assessments Draft Guidance Share page: Docket Number: FDA-2022-D-0810 CHPA appreciates the opportunity to provide comments on FDA Remote Regulatory Assessments Draft Guidance. Download Document Issues: OTC Medicines Dietary Supplements Consumer Medical Devices Related Posts Press Releases and Statements Tennessee Expands Access to OTC Cold & Allergy Medications Containing PSE May 7, 2024 Press Releases and Statements CHPA Response to Study Examining Prescription Acid Reflux Drugs Apr 25, 2024 Articles Polibrief: Consumer Data Privacy: State Efforts to Preserve Privacy Apr 16, 2024